FFA
ARKG icon

Fairfield Financial Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Fairfield Financial Advisors’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-30
Closed -$847 – 321
2022
Q4 		$847 Hold
30
– – ﹤0.01% 293
2022
Q3 		$986 Hold
30
– – ﹤0.01% 301
2022
Q2 		$945 Hold
30
– – ﹤0.01% 285
2022
Q1 		$1.38K Buy
+30
New +$1.43K ﹤0.01% 288

Other funds holding ARKG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Fairfield Financial Advisors's ARKG Position: Q1 2023 in Review

Fairfield Financial Advisors sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2023, closing a stake of 30 shares — an estimated $847 sold.

Fairfield Financial Advisors first reported a position in ARKG in Q1 2022 and held it in 4 quarters. The position peaked at $1.38K in Q1 2022. 295 funds tracked by Wall St. Rank hold ARKG as of Q1 2023.

  • Fairfield Financial Advisors reported no remaining ARK Genomic Revolution ETF position as of Q1 2023 after selling out during the quarter.
  • Fairfield Financial Advisors sold 30 ARK Genomic Revolution ETF shares in Q1 2023, an estimated $847.
  • Fairfield Financial Advisors first reported a position in ARK Genomic Revolution ETF in Q1 2022 and held it in 4 quarters.
  • Fairfield Financial Advisors's ARK Genomic Revolution ETF position peaked at $1.38K in Q1 2022.
  • 295 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2023.

Based on Fairfield Financial Advisors's 13F filing for Q1 2023, filed 4 Nov 2024.